SugarCone Biotech
MARCH 24, 2025
These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. Today, however, we turn to the TCE therapeutic class. Both explanations are plausible, but the relevant clinical data are limited. Proc Natl Acad Sci U S A 115: E2068-E2076.
Drug Target Review
APRIL 7, 2025
Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions. References Sun D, et al. 2022.02.002.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Codon
NOVEMBER 3, 2024
If present before vaccination, memory immune cells primed to destroy the environmental relatives might cross-react with and neutralize the BCG strain before it has a chance to set up an immune response against itself and M. Cell (2020). tuberculosis. Credit: Stokes J.M.
Codon
JUNE 5, 2025
The core of the CRISPR immune response is a guide RNA (gRNA) that binds to a CRISPR-associated (Cas) protein. Traditional approaches to this problem involve the use of viral vectors , which run the risk of triggering immune responses in patients. Collectively, these repeat-protospacer regions are known as CRISPR arrays.
The Pharma Data
AUGUST 16, 2021
Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.
addgene Blog
FEBRUARY 13, 2024
Antibodies administered as drugs are still immunogenic, meaning that they elicit an immune response from the body. Several factors contribute to the immunogenicity of a drug including the product origin; purity, mechanism, and stability; and sequence of biologic product, mode of administration, and dose (Lu et.al.,
The Pharma Data
NOVEMBER 10, 2020
Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. The interim analysis from the phase 1 trial has been published online at the preprint server, medRxiv.
Expert insights. Personalized for you.
Let's personalize your content